论文部分内容阅读
目的:探讨血管免疫母T细胞性淋巴瘤(angioimmunoblastic T-cell lymphoma,AITL)的病理、临床特点和CHOP方案的近期疗效。方法:同时采用常规组织病理学、免疫组织化学、细胞遗传学对15例淋巴瘤患者淋巴结的手术活检标本进行研究,并以CHOP方案作为初始治疗,复发后以MINE+P方案解救。结果:15例患者均表达T细胞抗原CD45RB、CD3和CD45RO,10例(10/15)表达CD10,10例(10/15)表达CD21,4例(4/14)染色体异常。全组15例均能评价疗效,15例CHOP方案初治有效率100%均有效,(CR 7例,PR 8例)。复发8例,MINE+P方案解救有效6例(CR 3例,PR 3例),有效率75%。毒副反应以粒细胞计数下降和血小板下降为常见,但均可耐受。结论:常规组织学、免疫组化检查、细胞遗传学是确诊AITL的重要手段,CHOP方案初治有效率高,但易复发,MINE+P方案解救有效率较高,毒副反应可以耐受。
Objective: To investigate the pathology and clinical features of angioimmunoblastic T-cell lymphoma (AITL) and the curative effect of CHOP regimen. Methods: The biopsy specimens of lymph nodes of 15 patients with lymphoma were studied by routine histopathology, immunohistochemistry and cytogenetics. CHOP regimen was used as the initial treatment, and MINE + P regimen was used to rescue the recurrence. Results: The T cell antigens CD45RB, CD3 and CD45RO were all expressed in 15 patients, CD10 was expressed in 10 patients (10/15), CD21 was expressed in 10 patients (10/15), and chromosome abnormalities were found in 4 patients (4/14). All 15 cases can evaluate the curative effect, 15 cases of CHOP regimen initial effective rate of 100% are effective (CR 7 cases, PR 8 cases). Recurrent in 8 cases, MINE + P program rescue effective in 6 cases (CR 3 cases, PR 3 cases), the effective rate of 75%. Toxicity to granulocyte count and platelet decline is common, but can be tolerated. CONCLUSION: Conventional histology, immunohistochemistry and cytogenetics are important methods for diagnosing AITL. CHOP regimen is effective in primary treatment, but relapse is easy. The rescue of MINE + P regimen is more efficient and toxic side effects can be tolerated.